{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,28]],"date-time":"2026-07-28T14:21:57Z","timestamp":1785248517736,"version":"3.55.0"},"reference-count":14,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,4,21]],"date-time":"2026-04-21T00:00:00Z","timestamp":1776729600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Gynecologic Oncology Reports"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1016\/j.gore.2026.102090","type":"journal-article","created":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T01:53:36Z","timestamp":1777600416000},"page":"102090","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Prolonged disease-free survival with immunotherapy combined with chemotherapy in a patient with advanced stage large cell neuroendocrine carcinoma of the uterus"],"prefix":"10.1016","volume":"65","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0847-2291","authenticated-orcid":false,"given":"Katherine","family":"Yoh","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie C.","family":"Smithgall","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabriela","family":"Tessler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amita","family":"Kulkarni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew T.","family":"Lenis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zahra","family":"Ghiassi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jason D.","family":"Wright","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shayan","family":"Dioun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.gore.2026.102090_b0005","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2021.653162","article-title":"Management of large cell neuroendocrine carcinoma","volume":"11","author":"Corbett","year":"2021","journal-title":"Front. Oncol."},{"issue":"14","key":"10.1016\/j.gore.2026.102090_b0010","doi-asserted-by":"crossref","first-page":"3449","DOI":"10.12998\/wjcc.v9.i14.3449","article-title":"Pure large cell neuroendocrine carcinoma originating from the endometrium: a case report","volume":"9","author":"Du","year":"2021","journal-title":"World J. Clin. Cases"},{"key":"10.1016\/j.gore.2026.102090_b0015","doi-asserted-by":"crossref","DOI":"10.1177\/2036361320968401","article-title":"Gynecologic large cell neuroendocrine carcinoma: a review","volume":"12","author":"Burkeen","year":"2020","journal-title":"Rare Tumors"},{"issue":"7","key":"10.1016\/j.gore.2026.102090_b0020","doi-asserted-by":"crossref","first-page":"2036","DOI":"10.1111\/1759-7714.13471","article-title":"Long-term survivor of pulmonary combined large cell neuroendocrine carcinoma treated with nivolumab","volume":"11","author":"Oda","year":"2020","journal-title":"Thorac Cancer."},{"key":"10.1016\/j.gore.2026.102090_b0025","article-title":"Advances in genetic profile and therapeutic strategy of pulmonary large cell neuroendocrine carcinoma","volume":"11","author":"Zhu","year":"2024","journal-title":"Front Med (Lausanne)."},{"issue":"23","key":"10.1016\/j.gore.2026.102090_b0030","doi-asserted-by":"crossref","first-page":"2220","DOI":"10.1056\/NEJMoa1809064","article-title":"First-line atezolizumab plus chemotherapy in extensive-stage small-cell lung cancer","volume":"379","author":"Horn","year":"2018","journal-title":"N. Engl. J. Med."},{"issue":"21","key":"10.1016\/j.gore.2026.102090_b0035","doi-asserted-by":"crossref","first-page":"2369","DOI":"10.1200\/JCO.20.00793","article-title":"Pembrolizumab or placebo plus etoposide and platinum as first-line therapy for extensive-stage small-cell lung cancer: randomized, double-blind, phase III KEYNOTE-604 study","volume":"38","author":"Rudin","year":"2020","journal-title":"J. Clin. Oncol."},{"issue":"1","key":"10.1016\/j.gore.2026.102090_b0040","doi-asserted-by":"crossref","first-page":"e13","DOI":"10.1016\/S1470-2045(24)00374-7","article-title":"Pulmonary neuroendocrine neoplasms: the molecular landscape, therapeutic challenges, and diagnosis and management strategies","volume":"26","author":"Sen","year":"2025","journal-title":"Lancet Oncol."},{"issue":"23","key":"10.1016\/j.gore.2026.102090_b0045","doi-asserted-by":"crossref","first-page":"2159","DOI":"10.1056\/NEJMoa2302312","article-title":"Pembrolizumab plus chemotherapy in advanced endometrial cancer","volume":"388","author":"Eskander","year":"2023","journal-title":"N. Engl. J. Med."},{"issue":"23","key":"10.1016\/j.gore.2026.102090_b0050","doi-asserted-by":"crossref","first-page":"2145","DOI":"10.1056\/NEJMoa2216334","article-title":"Dostarlimab for primary advanced or recurrent endometrial cancer","volume":"388","author":"Mirza","year":"2023","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.gore.2026.102090_b0055","article-title":"Complete response to immunotherapy combined with chemotherapy in a patient with gynecological mixed cancer mainly composed of small cell neuroendocrine carcinoma with high tumor mutational burden: a case report","volume":"12","author":"Su","year":"2022","journal-title":"Front. Oncol."},{"issue":"3","key":"10.1016\/j.gore.2026.102090_b0060","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1016\/j.ygyno.2020.05.682","article-title":"Phase II study of pembrolizumab efficacy and safety in women with recurrent small cell neuroendocrine carcinoma of the lower genital tract","volume":"158","author":"Frumovitz","year":"2020","journal-title":"Gynecol. Oncol."},{"issue":"53","key":"10.1016\/j.gore.2026.102090_b0065","article-title":"Long-term disease-free survival with chemotherapy and pembrolizumab in a patient with unmeasurable, advanced-stage dedifferentiated endometrial carcinoma","volume":"27","author":"Davis","year":"2024","journal-title":"Gynecol Oncol Rep."},{"issue":"2","key":"10.1016\/j.gore.2026.102090_b0070","doi-asserted-by":"crossref","first-page":"181","DOI":"10.6004\/jnccn.2023.0006","article-title":"Uterine neoplasms, version 1.2023, NCCN clinical practice guidelines in oncology","volume":"21","author":"Abu-Rustum","year":"2023","journal-title":"J. Natl. Compr. Canc. Netw."}],"container-title":["Gynecologic Oncology Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2352578926000706?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2352578926000706?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,17]],"date-time":"2026-06-17T04:05:15Z","timestamp":1781669115000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2352578926000706"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6]]},"references-count":14,"alternative-id":["S2352578926000706"],"URL":"https:\/\/doi.org\/10.1016\/j.gore.2026.102090","relation":{},"ISSN":["2352-5789"],"issn-type":[{"value":"2352-5789","type":"print"}],"subject":[],"published":{"date-parts":[[2026,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Prolonged disease-free survival with immunotherapy combined with chemotherapy in a patient with advanced stage large cell neuroendocrine carcinoma of the uterus","name":"articletitle","label":"Article Title"},{"value":"Gynecologic Oncology Reports","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.gore.2026.102090","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"102090"}}